Danaher(US:DHR) The Motley Fool·2025-10-21 18:17Core Insights - Danaher reported strong third-quarter earnings, exceeding both its own and market expectations, leading to a share price increase of up to 12.9% [1] Financial Performance - The company achieved core revenue growth of 3% and an adjusted operating profit margin of 27.9%, surpassing its forecast of low-single-digit revenue growth and a 25.5% profit margin [2] - Current market capitalization stands at $149 billion, with a current stock price of $223.69 and a gross margin of 61.52% [3] Business Segments - The outperformance is attributed to effective execution of the Danaher Business System (DBS) and strong growth in the bioprocessing business, particularly in the production of biologics like monoclonal antibodies [4] - The diagnostics segment, particularly Cepheid, experienced better-than-expected growth due to early customer purchases in anticipation of the respiratory season [5] Market Outlook - Management's preliminary guidance for 2026 indicates core revenue growth of 3% to 6% and high-single-digit earnings growth, which aligns with market expectations prior to the earnings report [7] - The stock is currently trading at nearly 29 times the estimated 2025 earnings, suggesting limited potential for significant price increases in the near term [7]